Best Low Price Stocks To Invest In Right Now

A few weeks ago, we published an article that characterized Gilead (GILD) as a “Value Trap.” That article was a follow-up to an earlier article which used our work on Gilead as an example of how a solid conceptual framework could help investors make better decisions. Both of these articles were based on a 16-page valuation report on Gilead we published to our members in September, 2016.

We caught a lot of flack for the recent characterization of Gilead as a value trap, but our opinion was redeemed on February 7th, when the stock fell heavily after a disappointing earnings announcement.

In today’s article, we’ll take another look at the valuation process – the most important weapon in an investor’s arsenal – in a continuation of the Gilead example. We would invite new readers to read through each of the earlier articles as well, to get a picture of the overall process!

Investing Anecdotes are Dangerous!

What interested us in September 2016, when we made our original analysis of Gilead, was the noise among the value investing community about what a deal Gilead was because the stock was trading at such a low Price-to-Earnings (P/E) ratio (See our article Three Things You Should Know About Gilead).

Best Low Price Stocks To Invest In Right Now: Cara Therapeutics, Inc.(CARA)

Advisors’ Opinion:

  • [By Max Byerly]

    Cara Therapeutics (NASDAQ:CARA) saw unusually large options trading on Thursday. Traders bought 6,902 call options on the company. This is an increase of 985% compared to the typical daily volume of 636 call options.

  • [By Stephan Byrd]

    Cara Operations (TSE:CARA) shares reached a new 52-week high during trading on Monday after Scotiabank raised their price target on the stock from C$33.50 to C$36.00. Scotiabank currently has an outperform rating on the stock. Cara Operations traded as high as C$28.70 and last traded at C$28.36, with a volume of 17713 shares trading hands. The stock had previously closed at C$27.39.

  • [By Keith Speights]

    It’s been a very good week for Cara Therapeutics, Inc. (NASDAQ:CARA). The biotech stock soared after Cara reported positive results froma phase 2/3 clinical study of intravenous (IV) CR845 in alleviating post-operative pain.

  • [By Chris Lange]

    Cara Therapeutics Inc. (NASDAQ: CARA) shares made a solid gain on Wednesday after the biotech announced positive results from a midstage trial. The positive top-line data comes from the firms adaptive Phase 2/3 trial of IV CR845 in patients undergoing abdominal surgeries.

Best Low Price Stocks To Invest In Right Now: Euronav NV(EURN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Teradyne, Inc. (NYSE: TER) fell 10.8 percent to $37.02 in pre-market trading after the company issued downbeat Q2 guidance.
    Edwards Lifesciences Corporation (NYSE: EW) fell 9.2 percent to $122.29 in pre-market trading. Edwards Lifesciences reported better-than-expected results for its first quarter, but issued weak earnings guidance for the second quarter.
    New Gold Inc. (NYSE: NGD) fell 8.8 percent to $2.30 in pre-market trading after rising 4.13 percent on Tuesday.
    Gold Fields Limited (ADR) (NYSE: GFI) fell 8.6 percent to $3.61 in pre-market trading.
    Natus Medical Incorporated (NASDAQ: BABY) fell 8.2 percent to $32.95 in pre-market trading after the company issued weak forecast for the second quarter.
    Atossa Genetics Inc. (NASDAQ: ATOS) shares fell 7.9 percent to $3.50 in pre-market trading after climbing 27.09 percent on Tuesday.
    Bright Scholar Education Holdings Limited (NYSE: BEDU) shares fell 6.7 percent to $13.58 in pre-market trading after reporting Q1 results.
    Sangamo Therapeutics Inc (NASDAQ: SGMO) fell 5.9 percent to $16.75 in pre-market trading following announcement of a $200 million common stock offering.
    Foresight Autonomous Holdings Ltd (NASDAQ: FRSX) shares fell 5.7 percent to $3.29 in pre-market trading after declining 3.32 percent on Tuesday.
    Euronav NV (NYSE: EURN) fell 4.8 percent to $8.40 in pre-market trading.
    Limelight Networks, Inc. (NASDAQ: LLNW) shares fell 4.3 percent to $4.69 in pre-market trading.
    Gaming and Leisure Properties Inc (NASDAQ: GLPI) shares fell 4.1 percent to $32.92 in pre-market trading after the company issued downbeat quarterly results and reported the retirement of CFO William Clifford

  • [By Logan Wallace]

    Seanergy Maritime (NASDAQ: SHIP) and Euronav (NYSE:EURN) are both small-cap transportation companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Best Low Price Stocks To Invest In Right Now: Banner Corporation(BANR)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Here are some of the news articles that may have impacted Accern’s rankings:

    Get Banner alerts:

    Banner Year for Asset Managers Could Be Catalyst for Change (markets.financialcontent.com) Zacks: Analysts Anticipate Banner Co. (BANR) to Announce $0.86 EPS (americanbankingnews.com) Banner Bank signs long lease for highly visible Sacramento site (finance.yahoo.com) Steven W. Rust Sells 511 Shares of Banner Co. (BANR) Stock (americanbankingnews.com) FY2018 Earnings Estimate for Banner Co. (BANR) Issued By DA Davidson (americanbankingnews.com)

    NASDAQ BANR opened at $57.47 on Friday. The company has a quick ratio of 0.90, a current ratio of 0.92 and a debt-to-equity ratio of 0.24. The firm has a market cap of $1,896.48, a P/E ratio of 19.22, a PEG ratio of 1.66 and a beta of 0.96. Banner has a 1 year low of $52.07 and a 1 year high of $62.75.

  • [By Max Byerly]

    BidaskClub cut shares of Banner (NASDAQ:BANR) from a buy rating to a hold rating in a research note published on Wednesday morning.

    Several other equities analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Banner from a hold rating to a sell rating in a research report on Tuesday, March 27th. Stephens reiterated a hold rating and set a $60.00 price objective on shares of Banner in a research report on Tuesday, April 24th. Seven equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Banner currently has an average rating of Hold and an average price target of $60.25.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Banner (BANR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Low Price Stocks To Invest In Right Now: El Paso Electric Company(EE)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Shares of El Paso Electric (NYSE:EE) have been assigned a consensus recommendation of “Hold” from the seven ratings firms that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $51.33.

Best Low Price Stocks To Invest In Right Now: Myriad Genetics, Inc.(MYGN)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Shares of gene-testing pioneer Myriad Genetics (NASDAQ:MYGN) rose 29% last month, according to data provided by S&P Global Market Intelligence. There were numerous positive announcements for investors to track, although the stock chart of the last several months summarizes Wall Street’s thoughts about all the moving parts. The genetics stock entered the month down over 17% from the beginning of 2018, but is now up 14% year to date.

  • [By Stephan Byrd]

    Myriad Genetics (NASDAQ:MYGN) was up 15.8% during mid-day trading on Tuesday after the company announced better than expected quarterly earnings. The company traded as high as $33.91 and last traded at $33.55. Approximately 2,379,822 shares were traded during trading, an increase of 235% from the average daily volume of 709,421 shares. The stock had previously closed at $28.98.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Myriad Genetics (MYGN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By ]

    Myriad Genetics (MYGN) : “This is an early stage company. Good spec, bad chart.”

    Skechers USA (SKX) : “I think they’re doing well. I think it’s really good and they’ve done a good job.”

Leave a Reply

Your email address will not be published. Required fields are marked *